Hiki ke hoʻopaneʻe ka Lapaʻau Hou i ka holomua o ka maʻi o Alzheimer

i kakauia ma hoʻoponopono

ʻO ka maʻi o Alzheimer (AD) a me nā maʻi dementia ʻē aʻe ke kumu i ke kaumaha o ka hoʻokele waiwai a me ka mālama olakino lehulehu ma ka honua holoʻokoʻa. Ke hoʻomau nei ka nui o ka poʻe e noho ana me ka dementia ma muli o ka ʻelemakule a me ka ulu ʻana. ʻO nā lāʻau lapaʻau i ʻae ʻia i kēia manawa no AD he hōʻailona a ʻaʻole ʻike ʻia e pili i ka piʻi ʻana o ka maʻi.

Hoʻolapala, PDF & Email

Ua hoʻolaha ʻo Moleac i ka hoʻokuʻu ʻana i nā hopena noiʻi ATHENE, i paʻi ʻia ma ka Journal of the American Medical Director Association (JAMDA).

ʻO nā lāʻau lapaʻau i hiki ke hoʻolōʻihi i ke kaʻina o AD i kona hiki ʻana i ke kahua lapaʻau, e noho mau i kahi pono olakino koʻikoʻi. Ua hōʻike ʻo NeuroAiD™II i nā hopena modulatory i ka amyloid precursor protein (APP) processing2 a me ka hoʻololi ʻana o ka protein tau i nā ʻano phosphorylated a aggregated abnormally3, a me nā waiwai neuro-regenerative a me neuro-restorative4. Ua hōʻike mua ʻia nā hopena maikaʻi o NeuroAiD™II ma nā hana cognitive impaired i ka ʻeha lolo traumatic5.

ʻO ka Alzheimer's Disease Therapy me NEuroaid (ATHENE) Study ka haʻawina mua e loiloi i ka palekana a me ka pono o NeuroAiD™II i nā maʻi AD haʻahaʻa a paʻa i nā maʻi maʻamau maʻamau.

ʻO ATHENE kahi hoʻāʻo ʻelua-makapō i hoʻopaʻa ʻia ma kahi o 6 mau mahina a ukali ʻia e ka hoʻonui ʻia ʻana o ka lepili o ka lāʻau NeuroAiD™II no 6 mau mahina. Ua hoʻokomo ʻia nā kumuhana 125 mai Singapore i ka hoʻokolokolo, i hoʻonohonoho ʻia e ka Memory Aging and Cognition Center, National University Health System, National Neuroscience Institute, a me St. Luke's Hospital, Singapore.

• Ua hōʻike ʻo NeuroAiD™II i ka palekana no ka wā lōʻihi ma ke ʻano he lāʻau hoʻohui i AD me ka piʻi ʻole o ka poʻe maʻi e loaʻa ana i nā hopena koʻikoʻi a i ʻole nā ​​hopena ʻino.

• ʻO ka hoʻomaka mua ʻana o NeuroAiD™II ua hāʻawi i ka hoʻomaikaʻi lōʻihi o ka cognition i hoʻohālikelike ʻia me kahi placebo (hui hoʻomaka hope) i ana ʻia e ka ADAS-cog, koʻikoʻi i ka helu ma 9 mau mahina, a me ka lohi i ka emi ʻana o ka manawa.

Kākoʻo nā hopena haʻawina ʻo ATHENE i ka pōmaikaʻi o NeuroAiD™II ma ke ʻano he lāʻau hoʻohui palekana i ka mālama maʻamau AD ma muli o ka loaʻa ʻole o ka hōʻike hōʻike o ka piʻi nui ʻana o nā hanana ʻino ma waena o MLC901 a me kahi placebo. Hōʻike nā loiloi i ka hiki o MLC901 i ka hoʻolōʻihi ʻana i ka piʻi ʻana o AD e kūlike me nā haʻawina preclinical a me nā noiʻi lapaʻau i paʻi mua ʻia, e lilo ia i mea lapaʻau hoʻohiki no nā maʻi maʻi AD. Pono kēia mau hopena i ka hōʻoia hou ʻana i nā haʻawina nui a lōʻihi.                                                         

He olelo na ka Luna Imi Nui

"ʻO ka maʻi Alzheimer ke kumu maʻamau o ka dementia, helu ʻia no 60-80% o nā hihia. Ma mua o ka ʻae ʻia ʻana o ka aducanumab e ka FDA, ʻaʻohe maʻi hoʻololi i ka mālama ʻana no ka maʻi Alzheimer, a ʻo nā lāʻau hōʻailona e loaʻa nei i kēia manawa ke ʻimi nei e hoʻopaneʻe iki i ka piʻi ʻana o nā hōʻailona dementia a hoʻomaikaʻi i ka maikaʻi o ke ola no ka poʻe me Alzheimer a me kā lākou mea mālama. No laila, pono e hāʻawi i nā mea maʻi a me kā lākou mea mālama i ke komo mua i ka maʻi maʻi a me nā lāʻau lapaʻau hou.

Pono e hoʻomaopopo ʻia nā hopena i hoʻohiki ʻia o ke aʻo ʻana ʻo ATHENE ma ke ʻano he ʻāpana o ka hoʻololi ʻana o ka pipeline hoʻomohala lāʻau maʻi Alzheimer mai ka hōʻailona i nā maʻi hoʻololi i nā maʻi. Pono e loiloi ʻia kēia noiʻi a me nā lāʻau lapaʻau ʻē aʻe e nā hoʻokolohua lapaʻau i hoʻolālā maikaʻi ʻia.

Kumu Christopher Chen

Luna Hoʻokele, Memory Aging and Cognition Center, National University Health System and Associate Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore.

Hoʻolapala, PDF & Email

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo